Eliem Therapeutics Inc

NASDAQ ELYM

Data sourced from

and

Download Data

Eliem Therapeutics Inc Net Income for the quarter ending March 31, 2024: USD -1.70 M

Eliem Therapeutics Inc Net Income is USD -1.70 M for the quarter ending March 31, 2024, a 92.39% change year over year. Net Income is the profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Eliem Therapeutics Inc Net Income for the quarter ending March 31, 2023 was USD -22.29 M, a -68.81% change year over year.
Eliem Therapeutics Inc Net Income for the quarter ending March 31, 2022 was USD -13.20 M, a 29.01% change year over year.
Eliem Therapeutics Inc Net Income for the quarter ending March 31, 2021 was USD -18.60 M, a -870.82% change year over year.
Eliem Therapeutics Inc Net Income for the quarter ending March 31, 2020 was USD -1.92 M.

NASDAQ: ELYM

Eliem Therapeutics Inc

CEO	Mr. Robert W. Azelby M.B.A.
IPO Date	Aug. 10, 2021
Location	United States
Headquarters	23515 NE Novelty Hill Road, Redmond, WA, United States, 98053
Employees	9
Sector	Healthcare
Industry	Biotechnology

Description

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Key trends